Angiogénesis
Los inhibidores de la angiogénesis son compuestos que interfieren con la formación de nuevos vasos sanguíneos, un proceso crucial en el crecimiento y la metástasis del cáncer. Al inhibir la angiogénesis, estos compuestos pueden restringir el suministro de sangre a los tumores, ralentizando o deteniendo su crecimiento. Los inhibidores de la angiogénesis son esenciales en la investigación del cáncer y en el desarrollo terapéutico, proporcionando información sobre los mecanismos de progresión tumoral y ofreciendo posibles tratamientos para el cáncer y otras enfermedades relacionadas con la angiogénesis. En CymitQuimica, ofrecemos una amplia gama de inhibidores de la angiogénesis de alta calidad para apoyar su investigación en oncología y biología vascular.
Subcategorías de "Angiogénesis"
- BTK(165 productos)
- Bcr-Abl(117 productos)
- EGFR(562 productos)
- FAK(72 productos)
- FLT(89 productos)
- Receptor del factor de crecimiento de fibroblastos (FGFR)(177 productos)
- JAK(245 productos)
- PDGFR(127 productos)
- RAAS(86 productos)
- Src(82 productos)
- Syk(37 productos)
- Trombina(51 productos)
- VDA(2 productos)
- VEGFR(239 productos)
Mostrar 6 subcategorías más
Se han encontrado 2246 productos de "Angiogénesis"
Ordenar por
Pureza (%)
0
100
|
0
|
50
|
90
|
95
|
100
EGFR-IN-139
CAS:EGFR-IN-139 (compound PD 18) is an EGFR inhibitor with IC50 values of 12.88 nM (wild type), 10.84 nM (L858R/T790M), and 42.68 nM (L858R/T790M/C797S). It demonstrates significant anticancer activity against the A549 and H1975 cancer cell lines, which express high levels of EGFR. EGFR-IN-139 exhibits strong selectivity for cancer cells and can be utilized in research on non-small cell lung cancer (NSCLC).Fórmula:C27H25ClN2O4Forma y color:SolidPeso molecular:476.951VEGFR-2-IN-10
VEGFR-2-IN-10 has enhanced antiangiogenic potency against VEGFR2 phosphorylation induced by VEGF with an IC50 value of 0.7 μM and no cytotoxic effects.Fórmula:C20H21N3O2Forma y color:SolidPeso molecular:335.4MM-589
CAS:MM-589 is a potent WD repeat domain 5 (WDR5) inhibitor and mixed lineage leukemia (MLL) protein-protein interaction.Fórmula:C28H44N8O5Pureza:98%Forma y color:SolidPeso molecular:572.70Lomonitinib
CAS:Lomonitinib is a potent and selective pan-FLT3/IRAK4 inhibitor with antitumor properties. It shows promise for research in myeloid leukemia.
Fórmula:C27H24N4O2Forma y color:SolidPeso molecular:436.505EGFR-IN-146
CAS:EGFR-IN-146 is an EGFR inhibitor that suppresses the EGFR signaling pathway and improves insulin sensitivity by activating the AMPK pathway. It effectively reduces blood glucose levels and body weight, showing great potential in the study of diabetes and obesity.Fórmula:C20H16N4Forma y color:SolidPeso molecular:312.368MTX-216
CAS:MTX-216 is an ATP-competitive inhibitor targeting both PI3K and EGFR. It simultaneously inhibits Ki-67 and ribosomal S6 phosphorylation, inducing apoptosis in NF1LOF cells. Additionally, MTX-216 suppresses SYK kinase activity with an IC50 of 281 nM. This compound is applicable for melanoma research.Fórmula:C22H14Cl2FN5O2SForma y color:SolidPeso molecular:502.348BMS-986143
CAS:BMS-986143: oral BTK inhibitor, IC50=0.26 nM, potential for autoimmune research, also targets TEC, BLK, BMX, TXK, YES1, ITK.Fórmula:C31H24Cl2N4O4Forma y color:SolidPeso molecular:587.45JAK3/BTK-IN-4
CAS:JAK3/BTK-IN-4, a dual inhibitor for JAK3/BTK, shows synergy in autoimmune disease treatment. (Patent WO2021147953A1, compound 003)Fórmula:C21H25ClN8OForma y color:SolidPeso molecular:440.93FLT3-IN-13
FLT3-IN-13 inhibits topoisomerase II/FLT3 in leukemia with IC50 of 2.26 μM, causes G2/M arrest, and promotes apoptosis.Fórmula:C20H14N4O2Forma y color:SolidPeso molecular:342.35FGFR4-IN-4
CAS:FGFR4-IN-4 is a FGFR4 inhibitor with anti-tumor activity.Fórmula:C28H32Cl2N6O5Pureza:98%Forma y color:SolidPeso molecular:603.5FLT3/ITD-IN-1
FLT3/ITD-IN-1 inhibits FLT3-ITD with IC50s: 38.2 nM (FLT3) and 144.1 nM (ITD), and fights acute myeloid leukemia.Fórmula:C19H22N6O2Forma y color:SolidPeso molecular:366.42HER2-IN-9
HER2-IN-9, an oral HER2 inhibitor (IC50: 0.03 μM), hinders growth and spread of HER2+ breast cancer.Fórmula:C19H14BrF3N2OForma y color:SolidPeso molecular:423.23BML-265
CAS:BML-265 is a potent inhibitor of EGFR tyrosine kinase (EGFR tyrosine kinase). It disrupts Golgi apparatus integrity in human cells and hinders the transport of secretory proteins across various substances. In contrast, BML-265 does not affect the integrity and transport of the Golgi apparatus in rodent cells.Fórmula:C18H15N3O2Forma y color:SolidPeso molecular:305.331VEGFR-2-IN-11
VEGFR-2-IN-11 is a potent inhibitor of VEGFR-2 (IC50: 60.27 nM) with an IC50 value of 60.27 nM, which induces apoptosis and has anticancer activity.Fórmula:C29H22BrN5SForma y color:SolidPeso molecular:552.49ERBB agonist-1
CAS:ERBB agonist-1, ERBB4 agonist (EC50=10.5 μM), induces receptor dimerization/phosphorylation of Akt and ERK1/2, cardioprotective.Fórmula:C24H25N3O2SPureza:99.90%Forma y color:SolidPeso molecular:419.54Ref: TM-T204401
1mgA consultar5mgA consultar10mg124,00€25mg241,00€50mg358,00€100mgA consultar1mL*10mM (DMSO)94,00€FAK-IN-26
CAS:FAK-IN-26 is a blood-brain barrier-penetrating inhibitor of Focal Adhesion Kinase (FAK) with an IC50 of 0.87 nM. It significantly reduces tumor cell viability, cancer stem cell activity, and cell migration in A549 and SKOV-3 cell lines. FAK-IN-26 exhibits potent anticancer activity, achieving tumor inhibition rates of 59.15% and 57.9% in A549 and SKOV-3 tumor mouse models, respectively.
Fórmula:C20H19BrFN5O2Forma y color:SolidPeso molecular:460.30(Rac)-PT2399
CAS:(Rac)-PT2399 is a potent and specific inhibitor of hypoxia-inducible factor 2a (HIF-2α)(IC50 of 0.01 μM).Fórmula:C17H10F5NO4SForma y color:SolidPeso molecular:419.32(-)-Cevimeline hydrochloride hemihydrate
(-)-Cevimeline HCl hemihydrate, a muscarinic agonist, treats Sjogren's xerostomia. Quick absorption, species-dependent metabolism.Fórmula:C10H19ClNO1·5SPureza:98%Forma y color:SolidPeso molecular:244.78VEGFR-2-IN-26
CAS:VEGFR-2-IN-26 inhibits VEGFR-2 (IC50: 15.5 nM), combating various cancers' cell growth.Fórmula:C24H19F3N6O2Forma y color:SolidPeso molecular:480.44JAK-IN-19
JAK-IN-19 inhibits JAK (pIC50: 7.2, 7.7), less so for VEGFR2 (7.0) and Aurora B (5.8).Fórmula:C26H36FN5O2Forma y color:SolidPeso molecular:469.59
